Company profile
Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06218290 | phase2 | completed | 2023-12-15 | 2024-05-29 | Unicycive Therapeutics, Inc | A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis |
FDA applications (0)
No records yet.